Research Updates

Prior to 1998, doctors could not agree on whether intraocular pressure (IOP) was involved in optic nerve damage, even when IOP was in the normal range. But a study sponsored by Glaucoma Research Foundation changed all that!

Glaucoma, a neurodegenerative disease and a leading cause of irreversible blindness, is closely correlated with biological age, but the underlying mechanisms aren’t fully understood.

“Innovative research really can move things forward. We can make things better for our patients by improving our understanding of this very complex disease.”

Researchers are looking for new types of treatments that do more than just lower eye pressure.

Since 1978, Glaucoma Research Foundation has been investing in high-risk/high-reward research programs in the form of Shaffer Grants.

The future of glaucoma care is taking shape now. New contact lens technologies could make it easier for patients to comply with their medication plans and monitor changes in their eye pressure.

Glaucoma Research Foundation is currently funding two multi-year Catalyst for a Cure research teams.

Prism glasses are part of a growing field of vision rehabilitation that focuses on living better with the vision you have.

Researchers are working on some amazing things that artificial intelligence (AI) can do for glaucoma sufferers, especially in the areas of diagnosis and disease management.

The Shaffer Prize recognizes a researcher whose project best exemplifies the pursuit of innovative ideas in the quest to better understand and cure glaucoma.

Neuroprotection represents a promising frontier in the treatment of glaucoma, offering hope and new avenues for preserving your sight.

The future of glaucoma research holds immense promise. With each discovery we move closer to achieving more effective treatments and, ultimately, a cure for glaucoma.

The Catalyst for a Cure research teams are generating insights and results as they seek new treatments and cures for glaucoma and other neurodegenerative diseases.

A new study explored whether mitochondrial function is associated with the rate at which glaucoma patients lose vision.

Two Concurrent Catalyst Initiatives Push for a Glaucoma Cure — and More

Glaucoma Research Foundation is dedicated to scientific research that deepens our understanding of glaucoma, generates new treatments, and will ultimately lead to a cure.

Glaucoma and Alzheimer’s Disease are two of the most severe age-related conditions affecting millions worldwide.

The Catalyst for a Cure Vision Restoration Initiative (CFC3) is seeking innovative ways to regrow or replace retinal ganglion cells and axons, which make up the optic nerve.

The Melza M. and Frank Theodore Barr Foundation Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration began their investigations in 2022.

Currently, there is extensive research and development on “drop-free” or “drop-less” technologies for delivering glaucoma medications to the eye.

The Catalyst for a Cure Vision Restoration team has identified a set of three genes that, when inhibited, improve the survival of optic nerve cells in models of glaucoma.

Smart contact lenses use tiny sensors to collect data about the pressure inside your eye. They can measure and monitor changes in IOP, or provide on-demand release of glaucoma medication.

“Neuroprotection: A New Path for Glaucoma Patients” was the topic of the 2022 Weston Family Lecture presented virtually on October 27, 2022.

What is neurodegeneration? And how will discoveries related to it affect people with glaucoma?

The Catalyst for a Cure Initiative to Prevent and Cure Neurodegeneration.